Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merck & Co

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Are Wall Street Analysts Predicting Merck & Co. Stock Will Climb or Sink?

Are Wall Street Analysts Predicting Merck & Co. Stock Will Climb or Sink?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

inkl

Read news from The Economist, FT, and more,
with one subscription

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

S&P Futures Gain With Focus on U.S. JOLTs Report and Corporate Earnings, FOMC Meeting on Tap

S&P Futures Gain With Focus on U.S. JOLTs Report and Corporate Earnings, FOMC Meeting on Tap

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors shift their focus from recent U.S. trade deals to economic data, a new round of corporate earnings reports, and the start of the Federal Reserve’s two-day policy meeting.

These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?

These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?

This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys.

Merck & Co Unusual Options Activity For December 02

Merck & Co Unusual Options Activity For December 02

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Broader Market Settles Mixed as Chip Stocks Slump

Broader Market Settles Mixed as Chip Stocks Slump

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.38%. US stocks settled mixed on Tuesday, with the Dow Jones Industrials posting a 1-1/2...

Earnings Preview: What to Expect From Merck & Co.'s Report

Earnings Preview: What to Expect From Merck & Co.'s Report

Merck & Co. is all set to announce its fiscal second-quarter results this month, and analysts are projecting a notable triple-digit earnings growth.

Get all your
news in one place.

100’s of premium titles.
One news app.

Stocks Tumble on Tech Stock Weakness and Signs of Persistent Inflation

The S&P 500 Index ($SPX ) (SPY ) this morning is down -1.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.83%. US stock indexes this morning are sharply lower, led by weakness in technology...

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

NY Attorney General Calls For Stronger Singulair Safety Warning

New York attorney general calls for stronger safety warning on popular asthma drug Singulair due to concerns about potential side effects.

Markets Today: Stocks Climb on M&A Activity and Lower Bond Yields

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.06%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.18%. Stock index futures this morning are moderately higher. An increase in M&A activity supports stocks after Boston Scientific agreed to buy Axionics for $3.7 billion and Johnson...

Get all your
news in one place.

100’s of premium titles.
One news app.

Stocks Finish Mostly Lower as Higher Bond Yields Undercut Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. Stocks on Thursday settled mixed, with the S&P...

Broader Market Gains on Positive Corporate News

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.13%. Stocks this morning are mixed, with the Nasdaq 100...

Branch out Your Portfolio With These 3 Diverse Stocks

The Federal Reserve’s interest rate hikes since last year showed results as annual inflation dropped for the ninth consecutive month in March. However, with the Fed likely to hike the interest rate at the policy meeting next month, the risk of a recession looms. In this scenario, it could be…

Tribune News Service

Pfizer to sell Paxlovid in China as COVID cases surge

Pfizer Inc. cemented a deal first announced in March to sell its antiviral medication Paxlovid in China through a state-owned company, adding to supply of COVID treatments in the country that’s now facing a massive infection surge.

J&J and Merck Ebola vaccines produce lasting antibodies in children and adults -studies

Ebola vaccines developed by Johnson Johnson and Merck Co produced virus-fighting antibodies and appear to be safe in children and adults, according to data from two studies published on Wednesday.

Indonesia to produce Merck's HPV vaccines to combat cervical cancer

Indonesia will produce drugmaker Merck Co's vaccines for human papillomavirus (HPV), the chief of its state-owned pharmaceutical company Bio Farma said on Tuesday, in a bid to combat HPV-linked cervical cancer in the country.

What Are Whales Doing With Merck & Co

A whale with a lot of money to spend has taken a noticeably bullish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 21 strange trades.

People

166,858 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

British Airways

the Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Cervical Cancer

Corporate Earnings

Human Papillomavirus

Places

340,709 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play